Format

Send to

Choose Destination
J Infect Dis. 2019 Oct 3. pii: jiz508. doi: 10.1093/infdis/jiz508. [Epub ahead of print]

Long-term immunogenicity of Measles vaccine: an Italian retrospective cohort study.

Author information

1
Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Bari, Italy.
2
Hygiene Department, Bari Policlinico General Hospital, Bari, Italy.

Abstract

BACKGROUND:

Levels of antibodies induced by the Measles virus containing vaccine have been shown to decline over time, but actually there is not a formal recommendation about the opportunity of testing immunized subjects (in particular, HCWs) to investigate the persistence of Measles IgG.

METHODS:

This study aims to evaluate the long-time immunogenicity of Measles vaccine in a sample of medical students and residents of the University of Bari who attended the Hygiene Department for the biological risk assessment (April 2014-June 2018).

RESULTS:

2,000 immunized (2 doses of MMR vaccine) students and residents have been tested. 305/2,000 (15%) subjects didn't show protective anti-Measles IgG. This proportion was higher among vaccinated at ≤15 months (20%) than in vaccinated at 16-23 months (17%) and at ≥24 months (10%; p<0.0001). After an MMR vaccine booster dose, we noted a seroconversion of 74% of seronegative HCWs. The overall seroconversion rate after a second dose booster was of 93%. No serious adverse events were noted after the booster doses.

CONCLUSIONS:

An important proportion of subjects immunized for Measles don't show a protective IgG titer in the 10 years after the vaccination. Our management strategy seems consistent with the purpose of evidencing immunological memory.

KEYWORDS:

booster dose; duration of immunization; healthcare workers

PMID:
31580436
DOI:
10.1093/infdis/jiz508

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center